Notable examples include KRAS mutations in colorectal tumors predicting resistance to anti-epidermal growth factor receptor (EGFR) targeting monoclonal antibodies (cetuximab [ImClone and Bristol-Myers Squibb]; and panitumumab [Amgen]) [4], [5], and KIT mutations predicting antitumor responses to imatinib (Novartis) in gastrointestinal stromal tumors [6]. This evidence concerns the gene EGFR and colorectal neoplasm.